![](https://sbx-attachments-production.s3.us-east-2.amazonaws.com/d90ly9teiy2vkfpgremgv2av5rf1?response-content-disposition=inline%3B%20filename%3D%22Structural-model-of-SARS-CoV-2-infection---Oo-422117.png%22%3B%20filename%2A%3DUTF-8%27%27Structural-model-of-SARS-CoV-2-infection---Oo-422117.png&response-content-type=image%2Fpng&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIA6MHW4YOXXGMMU2FH%2F20240908%2Fus-east-2%2Fs3%2Faws4_request&X-Amz-Date=20240908T000919Z&X-Amz-Expires=172800&X-Amz-SignedHeaders=host&X-Amz-Signature=af55877062bfd16e008084147ec21467145efd773d3e785a582ce61ae5fc05d1)
COVID took the world by stunned surprise – but, to quote an old Who song, we won't be fooled again.
That's thanks to accelerated genome sequencing technologies, expanded laboratory capabilities, and interacting infrastructure on a global level. These factors are converging to enable both identification of novel infectious diseases as well as microbial resistance, before these threats can impact public health, write a team from the European Society for Clinical Microbiology and Infectious Diseases in Frontiers in Science.
To continue reading, go to DNA Science, where this post first appeared.